In preclinical studies, the LRRC15-targeting antibody-drug conjugate ABBV-085 showed antitumor effect in breast cancer and ovarian cancer (Purcell et al., 2018; Ray et al., 2022). Here, LRRC15 is linked to breast carcinoma.